Peptides in Belize: a guide for Belizean physicians

Who this guide is for

This guide is for the Belizean physician who wants the facts before forming an opinion. Peptides are not a passing fad: they are one of the most successful drug classes in modern medicine¹. But in Belize the conversation often arrives through informal channels: supplements spiked with undeclared drugs, products sold by street vendors and online, and pharmacies operating without the licences the law requires¹⁰¹³¹⁴. Here is what the evidence shows, what the law of Belize actually says, and what the Ministry of Health and Wellness (MoHW) has done about it.

Peptides: an established drug class

Since insulin, more than 80 peptide drugs have reached the market¹. The GLP-1 receptor agonists are the best-known recent example. In the STEP 1 trial, 1,961 adults with overweight or obesity lost a mean 14.9 % of body weight over 68 weeks with weekly semaglutide, against 2.4 % with placebo³. In SURMOUNT-1, 2,539 adults lost 15.0 % to 20.9 % at 72 weeks across three tirzepatide doses, against 3.1 % with placebo⁴. And in the randomized SELECT trial, semaglutide reduced the composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke by 20 % (hazard ratio 0.80) in 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes². In the United States, 12 % of adults told pollsters in November 2025 that they were currently taking a GLP-1 drug, and 18 % had taken one at some point⁵.

What the law of Belize says

The core instrument is the Food and Drugs (Registration, Licensing and Inspection) Regulations, 2017 (Statutory Instrument No. 54 of 2017, gazetted 29 July 2017), made by the Minister responsible for health under section 55 of the Food and Drugs Act, Chapter 291 of the Substantive Laws of Belize⁶. The "competent authority" that applies them is the Director of Health Services or a nominee in the Ministry⁶. The key provisions:

• What counts as a drug. Any substance or mixture, for internal or external use, "manufactured, sold or represented for use in" the diagnosis, treatment, mitigation or prevention of a disease or its symptoms in man, or in "restoring, correcting or modifying organic functions in man" (regulation 2). The test is what the product is manufactured, sold or represented for⁶.
• No registration, no sale. "A person shall not commercialize any drug, unless that person has obtained registration of, and receives a product licence for, that drug from the competent authority" (regulation 3(1)). To commercialize means to make available on the market. Breaking this rule is an offence punishable on summary conviction by a fine not exceeding $10,000 (regulation 3(3)); the Minister may grant exemptions (regulation 3(2))⁶.
• What registration requires. A valid GMP certificate, a WHO-model Certificate of Pharmaceutical Product (or a Certificate of Free Sale), a certificate from the health authority of the country of origin, the manufacturer's certificate of analysis of the finished drug, technical and pharmacological information, label and package samples, and a fee of $100 for each drug per importer; documents must be in English or translated (regulation 4)⁶.
• Grounds for refusal. The authority must refuse a product licence if the risk-benefit analysis is unfavourable, if there is insufficient justification for therapeutic efficacy, or if the drug does not have the declared composition or its quality is compromised (regulation 6(4))⁶.
• Orphan drugs. A drug for a rare disease needs no registration, but it may not be imported or commercialized without a written import authorization; breach carries a fine of up to ten thousand dollars (regulation 5)⁶.
• Licensed premises only. Any premises from which drugs are stored, sold, dispensed or supplied to the public is a "pharmaceutical facility" and its owner must apply for a facility licence; failing to do so is an offence carrying a fine of up to ten thousand dollars (regulation 10). The authority inspects before granting it, the licence lasts one year and must be displayed (regulations 11, 12 and 17)⁶.
• Enforcement tools. The regulations give inspectors defined powers and set procedures for confiscation or destruction and for revocation or cancellation of licences (Part 4, regulations 19 to 26)⁶.

Prescription rules sit alongside this framework. In April 2026 the Ministry stated that it had introduced no new prescription requirement, classed contraceptives as prescription medicines, urged patients with diabetes, hypertension, high cholesterol or asthma to keep their follow-up visits, and directed questions to its Drug Inspectorate Unit⁷. In April 2026 the Ministry and the Pharmacists Association of Belize agreed a twelve-month phased enforcement for chronic-disease medicines, while antibiotics and controlled substances stay under strict prescription rules with no exceptions⁹.

Recent cases in Belize

• Fort Street pharmacies (ruling January 2026). Ministry inspectors, accompanied by police, closed four pharmacies at the Fort Street Tourism Village in Belize City on 10 August 2022 and seized pharmaceutical products¹⁰. Amandala reported that a "large amount" of controlled drugs was taken from two of them¹¹. Justice Nadine Nabie found that the pharmacies had operated without proper licences since the 2017 regulations took effect and lacked registered chemists and licences to sell controlled drugs and antibiotics; all claims were dismissed with costs¹⁰.
• Tainted supplements (March 2025). The Ministry warned that Artri King, Artribion, Artri Ajo King and Vitafer, found in the Cayo, Orange Walk, Stann Creek and Belize districts, contain undeclared substances¹³.
• "Royal Honey" (June 2025). After alerts from the US Food and Drug Administration and the Costa Rican health ministry, the Ministry warned against this sexual-enhancement product, falsely promoted as "natural" and sold online and by informal vendors¹⁴.
• Pharmacy closures (2018). The Ministry closed three pharmacies in the Cayo and Stann Creek districts for operating without a certified pharmacist and selling unauthorized drugs¹².
• Building pharmacovigilance (August 2026). A Ministry and PAHO/WHO workshop in Belize City brought together the Drug Inspectorate Unit, hospital and private pharmacists, importers and wholesalers on adverse-reaction reporting and suspected substandard and falsified products, using VigiFlow and VigiMobile¹⁶.

The evidence map

Not everything sold as a "peptide" sits on the same level of evidence. GLP-1 receptor agonists have phase 3 trials with hard cardiovascular outcomes². At the other end, a 2025 systematic review of BPC-157 found 36 studies: 35 preclinical and a single clinical study; it found no clinical safety data¹⁸. In between sits a live regulatory debate: in July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend six of seven peptides it reviewed (BPC-157, KPV, TB-500, MOTS-c, epitalon and semax) for the list of bulk substances that compounding pharmacies may use; emideltide failed¹⁹.

How safe are they?

Approved peptides have well-characterized safety profiles. In SELECT, 16.6 % of patients on semaglutide and 8.2 % on placebo stopped treatment because of adverse events². On 3 March 2026, PAHO reported "increasing reports of adverse events" tied to GLP-1 misuse in the Americas: mostly temporary gastrointestinal effects, but also acute pancreatitis, gallbladder disease and intestinal obstruction¹⁵. It warned that demand pushes sales into "unofficial channels, including the internet and social media," where products may carry wrong doses, different active ingredients or undeclared substances, and it cautioned against use "for exclusively aesthetic purposes" without clinical assessment¹⁵. For investigational peptides, the main problem is the absence of human studies rather than proven harm¹⁸.

Belize's own cases make the same point: the most concrete risk lies in where the product comes from. A product that was never registered, never inspected and is sold outside a licensed facility has no traceability, whatever the molecule⁶¹³¹⁴.

What it means for practice

Patients will arrive with questions, or with products. The Director of Health and Wellness has described the prescription as the result of "a proper doctor or nurse consultation"⁸, and Belize's chronic-disease burden is large: estimates cited by the Ministry put diabetes at about 1 in 6 Belizeans and hypertension at about 1 in 4¹⁷. The Ministry asks the public to report questionable health products to it¹³¹⁴, and PAHO asks countries to strengthen exactly that kind of pharmacovigilance¹⁵¹⁶. Back in 2017, when the registration regime started, the Belize Community Pharmacist's Association warned that its GMP certification requirement would force pharmacists to change suppliers²⁰; closures made under the regulations have since been upheld in court¹⁰. The physician who knows both the evidence and the rules becomes the patient's reference; if patients do not find that in the clinic, they will look for it on social media.